HF biomarkers have growing importance in daily clinical practice as well as in clinical trials. Several biomarkers are used for diagnosis and prognosis of HF patients. Recently, Galectine-3 has been proposed for diagnosis and prognosis of HF. In this study we aimed to determine the relationship between galectine-3 level and cardiac functions in patients with chronic heart failure and its correlation with clinical manifestations. The current study enrolled 90 patients with chronic heart failure and then divided according to ejection fraction (EF) into two groups, group I included 60 patients with clinical manifestation of HF and EF <50%, group II included patients with clinical manifestation of HF and EF >50%.serum levels of Galectine-3 were measured in all patients with heart failure. Level of galectine-3 was significantly increasing with advancing in diastolic dysfunction grade (P= <0.001). Plasma galectine-3 concentration can be used as a biomarker to aid in clinical staging and severity of heart failure.

Heart Failure (HF) remains one of the most prevalent and challenging medical conditions. Despite guideline – based therapy, HF is associated with high morbidity and mortality rates; such a way that 80% of men and 70% of women aged 65 years or above die within 8 years after the initial diagnosis. HF is also one of the most costly medical conditions [1]. This deleterious condition is associated with progressive ventricular dysfunction and cardiac remodeling [2]. Changes in cardiac structure and function often occur before the symptoms appear, resulting in difficulty in prediction of clinical outcomes. Thus, many patients require specialized imaging techniques, such as cardiac magnetic resonance imaging, which are not always available [3]. Risk factors, such as age, diabetes, and smoking, and severity of symptom are indicative of at risk patients, but are not enough to risk stratify patients [4]. The disease may even progress in the patients who are under treatment; therefore, it is necessary to monitor these patients during the course of treatment. HF biomarkers have growing importance in daily clinical practice as well as in clinical trials. Biomarkers can help in monitoring of response to therapy, prediction of patients outcome in clinical practice, and appropriate patient stratification [5]. Several biomarkers are used for diagnosis and prognosis of HF patients. Recently, Galectine-3 has been proposed for diagnosis and prognosis of HF patients. Galectine-3 is a product of active macrophages and plays a pivotal role in pathogenesis of remodeling, including inflammation and fibrosis in HF patients [6] so in this study we aimed to determine the relationship between galectine-3 level and left ventricular cardiac functions in patient with chronic heart failure and its correlation with clinical picture.

Thanks and Regards,

Alpine

Associate

Journal of Clinical Trials

clinicaltrials@eclinicalsci.com